Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension
Sponsor
Allergan (Industry)
Overall Status
Completed
CT.gov ID
NCT00168363
Collaborator
(none)
207
19
Study Details
Study Description
Brief Summary
This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 3 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
207 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Study Start Date
:
Jan 1, 2005
Actual Primary Completion Date
:
Aug 1, 2006
Actual Study Completion Date
:
Aug 1, 2006
Outcome Measures
Primary Outcome Measures
- lowering of intraocular pressure []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
ocular hypertension or glaucoma in both eyes
-
currently treated with brimonidine
-
requires IOP-lowering therapy in both eyes
Exclusion Criteria:
-
uncontrolled systemic disease
-
known allergy or sensitivity to brimonidine
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Allergan
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00168363
Other Study ID Numbers:
- 190342-022
First Posted:
Sep 15, 2005
Last Update Posted:
May 30, 2011
Last Verified:
May 1, 2011